Prodrugs utilised to improve tumour targeting
By targeting tumour cells more accurately, it may be possible to significantly improve the efficacy of antineoplastic therapy, say cancer specialists. The use of nontoxic prodrugs is being hailed as a possible way of achieving this goal. Progress is being made with both antibody-and gene-directed enzyme/prodrug therapy (ADEPT and GDEPT, respectively) in oncology laboratories around the world. Some of the latest developments were reported at the 25th Jubilee Conference of the New Zealand Society for Oncology [ Auckland, New Zealand; February 1996 ].